1. Zhou J, Sun H, Wang Z, et al. Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition). Liver Cancer. 2020; 9(6): 682–720. doi: 10.1159/000509424
2. Wang J, Qiu K, Zhou S, et al. Risk factors for hepatocellular carcinoma: an umbrella review of systematic review and meta-analysis. Annals of Medicine. 2025; 57(1): 2455539. doi: 10.1080/07853890.2025.2455539
3. Guo Q, Zhu X, Beeraka NM, et al. Projected epidemiological trends and burden of liver cancer by 2040 based on GBD, CI5plus, and WHO data. Scientific Reports. 2024; 14(1): 28131. doi: 10.1038/s41598-024-77658-2
4. Hafeez Bhatti AB, Dar FS, Waheed A, et al. Hepatocellular Carcinoma in Pakistan: National Trends and Global Perspective. Gastroenterology Research and Practice. 2016; 2016: 1–10. doi: 10.1155/2016/5942306
5. Zhu Y, Ge D, Wang J, et al. Emerging nanomedicine for liver diseases treatment. Journal of Nanobiotechnology. 2025; 23(1): 786. doi: 10.1186/s12951-025-03832-x
6. Chen Z, Xie H, Hu M, et al. Recent progress in treatment of hepatocellular carcinoma. American Journal of Cancer Research. 2020; 10(9): 2993–3036.
7. Nakajima M, Tokumitsu Y, Shindo Y, et al. The Recent Development of the Surgical Treatment for Hepatocellular Carcinoma. Applied Sciences. 2021; 11(5): 2023. doi: 10.3390/app11052023
8. Koza A, Bhogal RH, Fotiadis N, et al. The Role of Ablative Techniques in the Management of Hepatocellular Carcinoma: Indications and Outcomes. Biomedicines. 2023; 11(4): 1062. doi: 10.3390/biomedicines11041062
9. Seth I, Siu A, Hewitt L, et al. Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review. Journal of Gastrointestinal Cancer. 2023; 55(1): 318-331. doi: 10.1007/s12029-023-00961-0
10. Chang Y, Jeong SW, Young Jang J, et al. Recent Updates of Transarterial Chemoembolilzation in Hepatocellular Carcinoma. International Journal of Molecular Sciences. 2020; 21(21): 8165. doi: 10.3390/ijms21218165
11. Hamaya S, Oura K, Morishita A, et al. Cisplatin in Liver Cancer Therapy. International Journal of Molecular Sciences. 2023; 24(13): 10858. doi: 10.3390/ijms241310858
12. Hou Z, Liu J, Jin Z, et al. Use of chemotherapy to treat hepatocellular carcinoma. BioScience Trends. 2022; 16(1): 31–45. doi: 10.5582/bst.2022.01044
13. Rui R, Zhou L, He S. Cancer immunotherapies: advances and bottlenecks. Frontiers in Immunology. 2023; 14: 1212476. doi: 10.3389/fimmu.2023.1212476
14. Maki H, Hasegawa K. Advances in the surgical treatment of liver cancer. BioScience Trends. 2022; 16(3): 178–188. doi: 10.5582/bst.2022.01245
15. Huang A, Yang XR, Chung WY, et al. Targeted therapy for hepatocellular carcinoma. Signal Transduction and Targeted Therapy. 2020; 5(1): 146. doi: 10.1038/s41392-020-00264-x
16. Izzo F, Granata V, Grassi R, et al. Radiofrequency Ablation and Microwave Ablation in Liver Tumors: An Update. The Oncologist. 2019; 24(10): e990–e1005. doi: 10.1634/theoncologist.2018-0337
17. Llovet JM, Kelley RK, Villanueva A, et al. Hepatocellular carcinoma. Nature Reviews Disease Primers. 2021; 7(1): 6. doi: 10.1038/s41572-020-00240-3
18. Cheng K, Cai N, Zhu J, et al. Tumor-associated macrophages in liver cancer: From mechanisms to therapy. Cancer Communications. 2022; 42(11): 1112–1140. doi: 10.1002/cac2.12345
19. Chen W, Chiang CL, Dawson LA. Efficacy and safety of radiotherapy for primary liver cancer. Chinese Clinical Oncology. 2021; 10(1): 9. doi: 10.21037/cco-20-89
20. Bayda S, Adeel M, Tuccinardi T, et al. The History of Nanoscience and Nanotechnology: From Chemical–Physical Applications to Nanomedicine. Molecules. 2019; 25(1): 112. doi: 10.3390/molecules25010112
21. Priya M R K, Iyer PR. Antiproliferative effects on tumor cells of the synthesized gold nanoparticles against Hep2 liver cancer cell line. Egyptian Liver Journal. 2020; 10(1): 15. doi: 10.1186/s43066-020-0017-4
22. Mintz KJ, Leblanc RM. The use of nanotechnology to combat liver cancer: Progress and perspectives. Biochimica et Biophysica Acta (BBA)–Reviews on Cancer. 2021; 1876(2): 188621. doi: 10.1016/j.bbcan.2021.188621
23. Gabizon AA, Gabizon-Peretz S, Modaresahmadi S, et al. Thirty years from FDA approval of pegylated liposomal doxorubicin (Doxil/Caelyx): an updated analysis and future perspective. BMJ Oncology. 2025; 4(1): e000573. doi: 10.1136/bmjonc-2024-000573
24. Wang J, Zhang Y, Liu L, et al. Combined chemo/photothermal therapy based on mesoporous silica-Au core-shell nanoparticles for hepatocellular carcinoma treatment. Drug Development and Industrial Pharmacy. 2019; 45(9): 1487–1495. doi: 10.1080/03639045.2019.1629688
25. Zhang Y, Li M, Gao X, et al. Nanotechnology in cancer diagnosis: progress, challenges and opportunities. Journal of Hematology & Oncology. 2019; 12(1): 137. doi: 10.1186/s13045-019-0833-3
26. Dai Y, Han B, Dong L, et al. Recent advances in nanomaterial-enhanced biosensing methods for hepatocellular carcinoma diagnosis. TrAC Trends in Analytical Chemistry. 2020; 130: 115965. doi: 10.1016/j.trac.2020.115965
27. Kurczewska J. Chitosan-Based Nanoparticles with Optimized Parameters for Targeted Delivery of a Specific Anticancer Drug—A Comprehensive Review. Pharmaceutics. 2023; 15(2): 503. doi: 10.3390/pharmaceutics15020503
28. Yue M, Yang R, Jiang Y, et al. Precise construction of Regorafenib-loaded gold nanoparticles: investigation of antiproliferative activity and apoptosis induction in liver cancer cells. Journal of Experimental Nanoscience. 2023; 18(1): 2254006. doi: 10.1080/17458080.2023.2254006
29. Corma A, Botella P, Rivero-Buceta E. Silica-Based Stimuli-Responsive Systems for Antitumor Drug Delivery and Controlled Release. Pharmaceutics. 2022; 14(1): 110. doi: 10.3390/pharmaceutics14010110
30. Chinnappan R, Makhzoum T, Arai M, et al. Recent Advances in Biosensor Technology for Early-Stage Detection of Hepatocellular Carcinoma-Specific Biomarkers: An Overview. Diagnostics. 2024; 14(14): 1519. doi: 10.3390/diagnostics14141519
31. Ghosh G. Early detection of cancer: Focus on antibody coated metal and magnetic nanoparticle-based biosensors. Sensors International. 2020; 1: 100050. doi: 10.1016/j.sintl.2020.100050
32. Atapour A, Khajehzadeh H, Shafie M, et al. Gold nanoparticle-based aptasensors: A promising perspective for early-stage detection of cancer biomarkers. Materials Today Communications. 2022; 30: 103181. doi: 10.1016/j.mtcomm.2022.103181
33. Mondal R, Dam P, Chakraborty J, et al. Potential of nanobiosensor in sustainable agriculture: the state-of-art. Heliyon. 2022; 8(12): e12207. doi: 10.1016/j.heliyon.2022.e12207
34. Pathak S, Bazazordeh S, Çamlıca B, et al. Multianalyte nano-biosensor diagnostics: advances through microfluidic and AI integration. Frontiers in Bioengineering and Biotechnology. 2025; 13: 1715719. doi: 10.3389/fbioe.2025.1715719
35. Debnath N, Das S. Nanobiosensor: Current trends and applications. In: NanoBioMedicine. Singapore: Springer Singapore; 2020: p. 389–409. doi: 10.1007/978-981-32-9898-9
36. Shandilya R, Bhargava A, Bunkar N, et al. Nanobiosensors: Point-of-care approaches for cancer diagnostics. Biosensors and Bioelectronics. 2019; 130: 147–165. doi: 10.1016/j.bios.2019.01.034
37. Munawar A, Ong Y, Schirhagl R, et al. Nanosensors for diagnosis with optical, electric and mechanical transducers. RSC Advances. 2019; 9(12): 6793–6803. doi: 10.1039/c8ra10144b
38. Ahmad M, Hasan M, Tarannum N, et al. Recent advances in optical and photoelectrochemical nanobiosensor technology for cancer biomarker detection. Biosensors and Bioelectronics: X. 2023; 14: 100375. doi: 10.1016/j.biosx.2023.100375
39. Xu X, Zhou X, Xiao B, et al. Glutathione-Responsive Magnetic Nanoparticles for Highly Sensitive Diagnosis of Liver Metastases. Nano Letters. 2021; 21(5): 2199–2206. doi: 10.1021/acs.nanolett.0c04967
40. García-Ramírez JI, Luna-Cervantes M, Izaguirre-Hernández IY, et al. SERS-Based Immunoassay for α-Fetoprotein Biomarker Detection Using an Au-Ag Nanostars Platform. Biosensors. 2025; 15(9): 632. doi: 10.3390/bios15090632
41. Sheng J, Wang R, Yang H, et al. Surface-enhanced Raman scatting microfluidic chip based on the identification competition strategy were used for rapid and simultaneous detection of liver cancer related proteins. Photodiagnosis and Photodynamic Therapy. 2024; 49: 104336. doi: 10.1016/j.pdpdt.2024.104336
42. Jia W, Han Y, Mao X, et al. Nanotechnology strategies for hepatocellular carcinoma diagnosis and treatment. RSC Advances. 2022; 12(48): 31068–31082. doi: 10.1039/d2ra05127c
43. Malla RR, Kumari S, Kgk D, et al. Nanotheranostics: Their role in hepatocellular carcinoma. Critical Reviews in Oncology/Hematology. 2020; 151: 102968. doi: 10.1016/j.critrevonc.2020.102968
44. Chan MH, Lu CN, Chung YL, et al. Magnetically guided theranostics: montmorillonite-based iron/platinum nanoparticles for enhancing in situ MRI contrast and hepatocellular carcinoma treatment. Journal of Nanobiotechnology. 2021; 19(1): 308. doi: 10.1186/s12951-021-01052-7
45. Ma XH, Wang S, Liu SY, et al. Development and in vitro study of a bi-specific magnetic resonance imaging molecular probe for hepatocellular carcinoma. World Journal of Gastroenterology. 2019; 25(24): 3030–3043. doi: 10.3748/wjg.v25.i24.3030
46. Sawhney G, Bhardwaj AR, Sanu K, et al. Nanotechnology at the forefront of liver cancer diagnosis. In: Nanophototherapy. Amsterdam, The Netherlands: Elsevier; 2025. pp. 575–593. doi: 10.1016/b978-0-443-13937-6.00004-4
47. Meng X, Wu Y, Bu W. Functional CT Contrast Nanoagents for the Tumor Microenvironment. Advanced Healthcare Materials. 2020; 10(5): 2000912. doi: 10.1002/adhm.202000912
48. Goel S, England CG, Chen F, et al. Positron emission tomography and nanotechnology: A dynamic duo for cancer theranostics. Advanced Drug Delivery Reviews. 2017; 113: 157–176. doi: 10.1016/j.addr.2016.08.001
49. Lu X, Fu Y, Zhu Y, et al. Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer. Journal of Nanobiotechnology. 2024; 22(1): 614. doi: 10.1186/s12951-024-02879-6
50. Jin KT, Yao JY, Ying XJ, et al. Nanomedicine and Early Cancer Diagnosis: Molecular Imaging using Fluorescence Nanoparticles. Current Topics in Medicinal Chemistry. 2020; 20(30): 2737–2761. doi: 10.2174/1568026620666200922112640
51. Pratiwi FW, Kuo CW, Chen BC, et al. Recent Advances in the use of Fluorescent Nanoparticles for Bioimaging. Nanomedicine. 2019; 14(13): 1759–1769. doi: 10.2217/nnm-2019-0105
52. Zhang H, Deng L, Liu H, et al. Enhanced fluorescence/magnetic resonance dual imaging and gene therapy of liver cancer using cationized amylose nanoprobe. Materials Today Bio. 2022; 13: 100220. doi: 10.1016/j.mtbio.2022.100220
53. Yu X, Zhang Q, Wang L, et al. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma. Experimental Hematology & Oncology. 2025; 14(1): 62. doi: 10.1186/s40164-025-00658-z
54. Gabbia D, De Martin S. Toward a New Era in the Management of Hepatocellular Carcinoma: Novel Perspectives on Therapeutic Options and Biomarkers. International Journal of Molecular Sciences. 2023; 24(10): 9018. doi: 10.3390/ijms24109018
55. Addissouky TA, Sayed IETE, Ali MMA, et al. Latest advances in hepatocellular carcinoma management and prevention through advanced technologies. Egyptian Liver Journal. 2024; 14(1): 2. doi: 10.1186/s43066-023-00306-3
56. Ahn JC, Teng P, Chen P, et al. Detection of Circulating Tumor Cells and Their Implications as a Biomarker for Diagnosis, Prognostication, and Therapeutic Monitoring in Hepatocellular Carcinoma. Hepatology. 2021; 73(1): 422–436. doi: 10.1002/hep.31165
57. Xia W, Li H, Li Y, et al. In Vivo Coinstantaneous Identification of Hepatocellular Carcinoma Circulating Tumor Cells by Dual-Targeting Magnetic-Fluorescent Nanobeads. Nano Letters. 2020; 21(1): 634–641. doi: 10.1021/acs.nanolett.0c04180
58. Niroumand U, Motazedian MH, Ahmadi F, et al. Preparation and characterization of artemether-loaded niosomes in Leishmania major-induced cutaneous leishmaniasis. Scientific Reports. 2024; 14(1): 10073. doi: 10.1038/s41598-024-60883-0
59. Medda S, Mukhopadhyay S, Basu MK. Evaluation of the in-vivo activity and toxicity of amarogentin, an antileishmanial agent, in both liposomal and niosomal forms. Journal of Antimicrobial Chemotherapy. 1999; 44(6): 791–794. doi: 10.1093/jac/44.6.791
60. Li L, Zhang L, Montgomery KC, et al. Advanced technologies for molecular diagnosis of cancer: State of pre-clinical tumor-derived exosome liquid biopsies. Materials Today Bio. 2023; 18: 100538. doi: 10.1016/j.mtbio.2022.100538
61. Wu H, Wang M, Liang L, et al. Nanotechnology for Hepatocellular Carcinoma: From Surveillance, Diagnosis to Management. Small. 2021; 17(6): 2005236. doi: 10.1002/smll.202005236
62. Liu T, Liu L, Li L, et al. Exploiting targeted nanomedicine for surveillance, diagnosis, and treatment of hepatocellular carcinoma. Materials Today Bio. 2023; 22: 100766. doi: 10.1016/j.mtbio.2023.100766
63. Alghamdi MA, Fallica AN, Virzì N, et al. The Promise of Nanotechnology in Personalized Medicine. Journal of Personalized Medicine. 2022; 12(5): 673. doi: 10.3390/jpm12050673
64. Yuan XQ, Zhou N, Wang JP, et al. Anchoring super-enhancer-driven oncogenic lncRNAs for anti-tumor therapy in hepatocellular carcinoma. Molecular Therapy. 2023; 31(6): 1756–1774. doi: 10.1016/j.ymthe.2022.11.013
65. Huang KW, Hsu FF, Qiu JT, et al. Highly efficient and tumor-selective nanoparticles for dual-targeted immunogene therapy against cancer. Science Advances. 2020; 6(3): e.aax5032. doi: 10.1126/sciadv.aax5032
66. Baig B, Halim SA, Farrukh A, et al. Current status of nanomaterial-based treatment for hepatocellular carcinoma. Biomedicine & Pharmacotherapy. 2019; 116: 108852. doi: 10.1016/j.biopha.2019.108852
67. Wu S, Fan K, Yang Q, et al. Smart nanoparticles and microbeads for interventional embolization therapy of liver cancer: state of the art. Journal of Nanobiotechnology. 2023; 21(1): 42. doi: 10.1186/s12951-023-01804-7
68. Abdul Rahim R, Jayusman PA, Muhammad N, et al. Recent Advances in Nanoencapsulation Systems Using PLGA of Bioactive Phenolics for Protection against Chronic Diseases. International Journal of Environmental Research and Public Health. 2019; 16(24): 4962. doi: 10.3390/ijerph16244962
69. Radu ER, Semenescu A, Voicu SI. Recent advances in stimuli-responsive doxorubicin delivery systems for liver cancer therapy. Polymers. 2022; 14(23): 5249. doi: 10.3390/polym14235249
70. Wu M, Zhong C, Zhang Q, et al. pH-responsive delivery vehicle based on RGD-modified polydopamine-paclitaxel-loaded poly (3-hydroxybutyrate-co-3-hydroxyvalerate) nanoparticles for targeted therapy in hepatocellular carcinoma. Journal of Nanobiotechnology. 2021; 19(1): 39. doi: 10.1186/s12951-021-00783-x
71. Han Q, Du L, Zhu L, et al. Review of the Application of Dual Drug Delivery Nanotheranostic Agents in the Diagnosis and Treatment of Liver Cancer. Molecules. 2023; 28(20): 7004. doi: 10.3390/molecules28207004
72. Kher C, Kumar S. The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review. Cureus. 2022; 14(9): e29059. doi: 10.7759/cureus.29059
73. Lammers T. Nanomedicine Tumor Targeting. Advanced Materials. 2024; 36(26): e.2312169. doi: 10.1002/adma.202312169
74. Farjadian F, Ghasemi A, Gohari O, et al. Nanopharmaceuticals and Nanomedicines Currently on the Market: Challenges and Opportunities. Nanomedicine. 2018; 14(1): 93–126. doi: 10.2217/nnm-2018-0120
75. Yu X, Zhang Q, Wang L, et al. Engineered nanoparticles for imaging and targeted drug delivery in hepatocellular carcinoma. Experimental Hematology & Oncology. 2025; 14(1): 62. doi: 10.1186/s40164-025-00658-z
76. Huang F, Chen L, Zhang X, et al. Engineered nanomedicine targets liver cancer stem cells to treat liver cancer disease. Journal of Materials Chemistry B. 2025; 13(41): 13184–13205. doi: 10.1039/d5tb01278c
77. Xu J, Liu Y. Nanomaterials for liver cancer targeting: research progress and future prospects. Frontiers in Immunology. 2025; 16: 1496498. doi: 10.3389/fimmu.2025.1496498
78. Joshi VB, Geary SM, Gross BP, et al. Tumor lysate-loaded biodegradable microparticles as cancer vaccines. Expert Review of Vaccines. 2014; 13(1): 9–15. doi: 10.1586/14760584.2014.851606
79. Yao W, Liu C, Wang N, et al. An MRI-guided targeting dual-responsive drug delivery system for liver cancer therapy. Journal of Colloid and Interface Science. 2021; 603: 783–798. doi: 10.1016/j.jcis.2021.06.151
80. Xu X, Liu C, Wang Y, et al. Nanotechnology-based delivery of CRISPR/Cas9 for cancer treatment. Advanced Drug Delivery Reviews. 2021; 176: 113891. doi: 10.1016/j.addr.2021.113891
